Drug Database
RH

rhIFN-alpha (ReliFeron)

✓ Approved

Reliance Life Sciences Private Limited · IFNAR2 · Recombinant Proteins

What is rhIFN-alpha?

rhIFN-alpha is a recombinant proteins developed by Reliance Life Sciences Private Limited. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection or intravenous (iv) or subcutaneous injection.

Drug Profile

Brand NamesReliFeron
CompanyReliance Life Sciences Private Limited
Drug ClassRecombinant Proteins
Molecular TargetIFNAR2
RouteInjectable (Others), Intramuscular (IM) Injection, Intravenous (IV), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Reliance Life Sciences Private Limited

Mechanism of Action

Molecular Targets

rhIFN-alpha acts on 1 molecular target:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

rhIFN-alpha is developed for 8 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hairy cell leukaemia✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsHepatitis C✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-Hodgkin's lymphoma✓ Approved

+3 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedProgress in neurobiology2026-07-25

Low-frequency modulations bridge the Language and Default Mode networks.

Woolnough Oscar O, Murphy Elliot E, Dehaene Stanislas S, Tandon Nitin N

As you read this sentence, you integrate meanings of individual words into complex, higher-order representations. In addition to the core language network (LN), this dynamic process recruits other domain-general networks such as the default mode network (DMN), with which it partially overlaps anatomically but segregates from functionally. To evaluate interactions between LN and DMN, we extracted instantaneous frequency, power, and phase (4-30Hz) from intracranial electrodes in 32 participants who read sentences and wordlists. We isolated a complex low-frequency modulation, most reliably measured as a ramping of instantaneous frequency in the alpha band throughout sentences, greater than wordlists, occurring robustly across both the LN and DMN. Granger causal networks demonstrate this coincided with ramping increases in alpha-band connectivity between and within DMN and LN. We suggest that alpha-band modulations index dynamic interactions between core LN and broader domain-general networks and may be crucial for higher order semantic integration and the derivation of crossmodal knowledge from the language domain.

PMID 42498072
Read full article →
PubMedThe Medical clinics of North America2026-07-25

Pediatric Sleep Disorders: Taking Care of Gen Z and Gen Alpha.

Balasubramaniam Ramesh R, Parekh Srishti V SV, Parekh Vivasvan B VB, Parekh Bakul B

Pediatric sleep disorders are common, underrecognized conditions with significant short-term and long-term consequences for physical health, neurocognitive development, mental well-being, and family functioning. This article provides a comprehensive, clinically focused overview of pediatric sleep disorders, with particular emphasis on Generation Z and Generation Alpha cohorts who are uniquely shaped by pervasive digital exposure, circadian disruption, and contemporary psychosocial stressors. Normal developmental changes in sleep architecture are reviewed to distinguish physiologic variation from pathology. Key sleep disorders including insomnia, circadian rhythm sleep-wake disorders, sleep-disordered breathing, parasomnias, and sleep-related bruxism are discussed.

PMID 42498422
Read full article →
PubMedHNO2026-07-25

The European Board Examination in Otorhinolaryngology as a high-quality test instrument: psychometric measures in a long-term comparison.

Neudert Marcus M, Meric Hafiz Aysenur A, Ward Victoria V, Simo Ricard R et al.

The European Board Examination in Otorhinolaryngology, Head and Neck Surgery (EBEORL-HNS) is a Europe-wide specialty examination consisting of a written multiple-choice test and a standardized oral examination. Only limited psychometric analyses have been published to date. This study aimed to evaluate examination data from recent years and assess the formats regarding difficulty, reliability, and pass rates. Aggregated data from 2013-2024 were analyzed. Mean scores, standard deviations, item difficulty, item discrimination, Cronbach's alpha, and Angoff's score were calculated. The written and oral parts were examined descriptively and comparatively. The written examination demonstrated a mean difficulty of 67% (proportion of correctly answered items), a pass rate of 82%, and Cronbach's alpha of 0.83 (internal consistency). The passing cutoff (according to the Angoff method) was 59 points on average. The oral part showed a mean difficulty of 70%, a pass rate of 74%, and an average score of around 3.0 on a four-point scale. Year-to-year variability largely reflected differences in the international candidate cohorts. The findings confirm that the EBEORL-HNS demonstrates stable psychometric quality. Compared to national specialty examinations, it offers high transparency and clearly defined quality criteria. Variations in performance appear more related to heterogeneous training backgrounds than to shortcomings of the assessment tools.

PMID 42498845
Read full article →
PubMedFrontiers in pharmacology2026-07-25

Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review.

Altaher Hala H, Al-Mashhadani Mustafa M, Usman Rameen R, Ghelani Hardik H et al.

Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-α) that is widely used for induction and maintenance therapy in pediatric inflammatory bowel disease (IBD), yet its effects on the developing intestinal microbiome and treatment response remain unclear. To systematically synthesize evidence on IFX-associated microbiome changes in pediatric IBD and evaluate microbiome features linked to treatment response. A systematic review was conducted following the PRISMA 2020 guidelines. PubMed, Scopus, Embase, and CENTRAL were searched from database inception until March 2026, and our results were synthesized narratively. Of the 945 records identified, 13 studies met the inclusion criteria, comprising 242 pediatric patients. Findings for alpha diversity were variable across studies. In contrast, beta-diversity patterns, taxonomic profiles, and functional analyses more consistently showed positive IFX-associated microbial changes. Responders to treatment more frequently showed enrichment of beneficial taxa, including Faecalibacterium, Subdoligranulum, and Bifidobacterium, while non-responders exhibited a tendency towards dysbiotic microbial signatures, evidenced by increased levels of Gammaproteobacteria and Candida. Functional and metabolomic studies suggested beneficial shifts in bile-acid metabolism, short-chain fatty acid-related pathways, and inflammatory signaling post IFX treatment. Clinical and biochemical improvements with IFX were consistently reported; however, these improvements were not always accompanied by uniform recovery of overall microbial diversity. In pediatric IBD, IFX is more consistently associated with shifts in microbial composition and function than with broad increases in overall microbial diversity. Further large, standardized studies are warranted to refine the role of microbiome features in biologic treatment stratification. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251133625, identifier CRD420251133625.

PMID 42499495
Read full article →
PubMedWorld journal of otorhinolaryngology - head and neck surgery2026-07-25

Thai Translation and Validation of Chronic Rhinosinusitis-Patient Reported Outcome (CRS-PRO).

Chitsuthipakorn Wirach W, Pooldum Vorachai V, Phetpong Juthaporn J, Lawpoolsri Saranath S et al.

The Chronic Rhinosinusitis Patient-Reported Outcome (CRS-PRO) questionnaire was recently developed for use in chronic rhinosinusitis (CRS) patients. This instrument was developed using current diagnostic criteria. This study aimed to translate and validate CRS-PRO for Thai CRS patients. The three-phase translation process and validation were conducted at Rajavithi Hospital, a tertiary hospital in Bangkok, Thailand. Adults (> 18 years) with primary CRS, diagnosed using EPOS2020 criteria, were recruited alongside non-CRS controls. Discriminant validity was assessed by comparing scores between CRS patients and non-CRS controls. Concurrent validity was evaluated by correlating CRS-PRO with the Thai version of the Sinonasal Outcome Test-22 (SNOT-22). Reliability was assessed using internal consistency (Cronbach's alpha) and test-retest reliability using intraclass correlation coefficient (ICC). A total of 85 CRS patients and 40 non-CRS controls were enrolled. The Thai CRS-PRO was completed in (101.80 ± 26.36) seconds. CRS patients had significantly higher scores than controls (16 [10-24] vs. 2 [0-5], p < 0.001) (median [IQR]). CRS-PRO demonstrated strong concurrent validity with SNOT-22 (ρ = 0.82, p < 0.001), high internal consistency (Cronbach's alpha = 0.89), and high test-retest reliability (ICC = 0.81, 95% confidence interval 0.72-0.88). The Thai-translated CRS-PRO has been developed and validated. It demonstrated significant discriminant validity between patients and non-patients, a very strong correlation with the Thai version of SNOT-22, and good reliability. Its brevity and time efficiency support its applicability in both clinical practice and research, enhancing its potential for widespread adoption.

PMID 42500059
Read full article →
PubMedJPGN reports2026-07-25

Glutamine and partially hydrolyzed guar gum promote intestinal adaptation and modulate small intestinal microbiota in high-output stoma: A case report.

Kawaguchi Yunosuke Y, Terui Keita K, Takenouchi Ayako A, Komatsu Shugo S et al.

We report a case of a very low-birth-weight infant with a high-output stoma following necrotizing enterocolitis. The patient exhibited villous atrophy and microbial dysbiosis. Supplementation with glutamine and partially hydrolyzed guar gum (PHGG) was initiated, leading to reduced stoma output, improved feeding tolerance, and appropriate weight gain. Histological analysis revealed villous elongation, and microbiota analysis showed a shift from Proteobacteria dominance to increased Firmicutes and Actinobacteria abundance, along with increased alpha diversity. These findings suggest that glutamine and PHGG may support intestinal adaptation and microbiota modulation in infants with high-output stomas. However, conclusions should be drawn cautiously due to the limited generalizability of a single case.

PMID 42499729
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about rhIFN-alpha